Assay of the beta-glucosidase activity with natural labelled and artificial substrates in leukocytes from homozygotes and heterozygotes with the Norrbottnian type (Type 3) of Gaucher disease.
Leukocytes were isolated from 14 patients (7 males and 7 females ) with Gaucher disease of the Norrbottnian type (Type 3), 32 obligate heterozygotes (16 males and 16 females) for this disease and 20 controls (10 males and 10 females). After collection, the cells were transported in dry ice to the laboratory, where they were assayed. The assays were repeated after the cells had been stored for 12 months. beta-Glucosidase activity was assayed with D-[glucose-U-14C]glucosylceramide at pH 5.8 with Cutscum-Na-cholate as a detergent and 4-methylumbelliferyl-beta-glucoside at pH 4.1 with Triton-Na-taurocholate as a detergent. The activities of two marker enzymes, 4-methylumbelliferyl-beta-galactosidase and N-acetyl-beta-glucosaminidase, were assayed in aliquots of the same leukocyte samples. The activity of beta-galactosidase remained constant during storage, N-acetyl-beta-glucosaminidase increased, while beta-glucosidase decreased as assayed with the natural as well as with the artificial substrate. beta-Glucosidase activity was significantly lower in the female than in male controls and heterozygotes. When assayed with natural substrate beta-glucosidase activity in leukocytes from the male patients was 6--12% of the control mean value and 10--15% in those from the female patients. The corresponding figures found when the artificial substrate was used were 15--30% and 22--45%. The values for the heterozygotes were respectively 42--68% and 34--79% with the natural substrate, and 33--82% and 51--109% with the artificial substrate. No correlation was found between the age of the patient and the beta-glucosidase activity.
D000117:Acetylglucosamine / Q000031:analogs & derivatives*; D000118:Acetylglucosaminidase / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004355:Drug Stability; D005260:Female; D005697:Galactosides / Q000378:metabolism; D005776:Gaucher Disease / Q000201:enzymology* / Q000235:genetics; D005944:Glucosamine / Q000031:analogs & derivatives / Q000378:metabolism; D005959:Glucosidases / Q000378:metabolism*; D005960:Glucosides / Q000378:metabolism; D005962:Glucosylceramidase / Q000378:metabolism; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006923:Hymecromone / Q000031:analogs & derivatives / Q000378:metabolism; D007962:Leukocytes / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D012737:Sex Factors; D001616:beta-Galactosidase / Q000378:metabolism; D001617:beta-Glucosidase / Q000378:metabolism*
D005697:Galactosides; D005960:Glucosides; C014110:4-methylumbelliferyl glucoside; C025158:4-methylumbelliferyl 2-acetamido-2-deoxy-beta-D-glucopyranoside; D006923:Hymecromone; C026845:4-methylumbelliferyl-galactopyranoside; D005959:Glucosidases; D001617:beta-Glucosidase; D001616:beta-Galactosidase; D005962:Glucosylceramidase; D000118:Acetylglucosaminidase; D005944:Glucosamine; D000117:Acetylglucosamine